NTRK
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor
The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The European Commission will decide whether to approve Augtyro in these two indications in January 2025.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
Feb 16, 2022
Jan 27, 2021